Maharashtra State Pharmacy Council Partners with IPC to Launch Dedicated “Pharmacovigilance & Medicine Safety” Web Portal

Date:

Share post:

The Maharashtra State Pharmacy Council (MSPC), in a strategic collaboration with the Indian Pharmacopoeia Commission (IPC), announced the official launch of a dedicated “Pharmacovigilance & Medicine Safety” section on its official website.

Initiated under a Memorandum of Understanding (MoU) between the IPC and MSPC, this digital gateway aims to promote the rational use of medicines, strengthen regional adverse drug reaction monitoring, and maximize patient safety protocols across the state of Maharashtra.The new specialized section streamlines access to critical pharmacovigilance assets and regulatory frameworks, providing stakeholders with direct access and purchase links for the National Formulary of India (NFI),the latest real-time Drug Safety Alerts published under the Pharmacovigilance Programme of India (PvPI),Adverse Drug Reaction Monitoring System (ADRMS) QR Code designed for accelerated, on-the-go ADR reporting,an updated directory of accredited Adverse Drug Reaction Monitoring Centers (AMCs) operating across Maharashtra and multilingual ADR Reporting Forms for healthcare practitioners and consumers, available in English, Hindi, and regional vernacular languages.

MSPC leadership strongly encourages all registered pharmacists, pharmacy students, academicians, and healthcare professionals across clinical settings to utilize this portal actively to contribute toward building a safer, highly vigilant healthcare ecosystem.

Written by: Pragna Biswas

Graphics by: Pramit Hazra

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related articles

Bhawanipur Global Campus Announces iNATCONPH 2026: A Global Platform for Pharmacy & Allied Health Research

Kolkata: Bhawanipur Global Campus has announced the 16th International Conference - iNATCONPH 2026, a prestigious international scientific conference...

Emcure Pharma Receives CDSCO Approval to Launch Poviztra®️ for Fatty Liver Disease Treatment

Emcure Pharmaceuticals Ltd  announced that its co-marketed semaglutide brand, Poviztra®, has received regulatory approval from the Central Drugs...

CDSCO Partners with THSTI to Strengthen Vaccine and Healthcare innovation

The Central Drugs Standard Control Organization (CDSCO), India’s national regulatory authority, and the Translational Health Science and Technology...

EMeRG Launches Hospital Intel Suite™️ to transform MedTech Market

EMeRG, a leading healthcare intelligence provider with over a decade of industry expertise,  announced the launch of Hospital...